Northwest Biotherapeutics, Inc.
NWBO
$0.2657
-$0.0039-1.45%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 375.00K | 231.00K | 357.00K | 510.00K | 284.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 375.00K | 231.00K | 357.00K | 510.00K | 284.00K |
| Cost of Revenue | 8.35M | 10.52M | 8.13M | 8.29M | 7.94M |
| Gross Profit | -7.98M | -10.29M | -7.77M | -7.78M | -7.66M |
| SG&A Expenses | 9.34M | 8.21M | 7.03M | 9.68M | 8.09M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.69M | 18.73M | 15.16M | 17.97M | 16.03M |
| Operating Income | -17.31M | -18.50M | -14.80M | -17.46M | -15.74M |
| Income Before Tax | -19.34M | -28.22M | -19.37M | -17.87M | -18.31M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.34M | -28.22M | -19.37M | -17.87M | -18.31M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.34M | -28.22M | -19.37M | -17.87M | -18.31M |
| EBIT | -17.31M | -18.50M | -14.80M | -17.46M | -15.74M |
| EBITDA | -16.88M | -18.06M | -14.36M | -17.03M | -15.32M |
| EPS Basic | -0.01 | -0.02 | -0.02 | -0.02 | -0.02 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.01 | -0.02 | -0.02 | -0.02 | -0.02 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 1.36B | 1.31B | 1.26B | 1.21B | 1.19B |
| Average Diluted Shares Outstanding | 1.36B | 1.31B | 1.26B | 1.21B | 1.19B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |